Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), ...

A haematologist shares insights into the challenges of the disease and the promise of emerging treatment options.

Roche presents new and updated data for fixed-duration Columvi and Lunsumio at ASH 2024 meeting: Basel Wednesday, December 11, 2024, 11:00 Hrs [IST] Roche announced that new and u ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.

Researchers from City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ranked among ...

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class ...

ELM-1 is an ongoing, open-label, multicenter Phase 1 trial to investigate the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies previously treated with CD20-directed ...

Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with ...